Dysregulation of Human Phase I Enzymes in APAP Overdose Subjects with Low ALT Levels
Total Page:16
File Type:pdf, Size:1020Kb
Ouachita Baptist University Scholarly Commons @ Ouachita Honors Theses Carl Goodson Honors Program 2018 Dysregulation of Human Phase I Enzymes in APAP Overdose Subjects with Low ALT Levels Aaron Woodall Ouachita Baptist University Follow this and additional works at: https://scholarlycommons.obu.edu/honors_theses Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Woodall, Aaron, "Dysregulation of Human Phase I Enzymes in APAP Overdose Subjects with Low ALT Levels" (2018). Honors Theses. 655. https://scholarlycommons.obu.edu/honors_theses/655 This Thesis is brought to you for free and open access by the Carl Goodson Honors Program at Scholarly Commons @ Ouachita. It has been accepted for inclusion in Honors Theses by an authorized administrator of Scholarly Commons @ Ouachita. For more information, please contact [email protected]. SENIOR THESIS APPROVAL This Honors Thesis entitled "Dysregulation of Human Phase I Enzymes in APAP Overdose Subjects with Low AL T Levels" written by Aaron Woodall and submitted in partial fulfillment of the requirements for completion of the Carl Goodson Honors Program meets the criteria for acceptance and has been approved by the undersigned readers. Dr. Jim Taylor, thesis director Dr. Angela Douglass, second reader Dr. Myra Houser, third reader Dr. Barbara Pemberton, Honors Program director April 20, 2018 Dysregulation of Human Phase I Enzymes in AP AP Overdose Subjects with Low AL T Levels Aaron Woodall Background: Acetaminophen (APAP) is a common analgesic that can cause liver injury and death in high doses. Changes in gene expression following APAP overdose may be more sensitive indicators of liver injtrry than the current clinical indicator, alanine aminotransferase (ALT). The aim of this study was to examine gene expression of Phase I enzymes in pediatric AP AP overdose patients with low ALT levels (<75 lUlL), in order to understand the mechanism of APAP toxicity. Methods: Blood samples were collected from control patients (no AP AP exposure; N=5) and APAP overdose patients {N=S). Using the P AXgene system, RNA was extracted from the blood samples and eDNA was synthesized. Quantitative polymerase chain reaction (qPCR) was performed and samples were profiled with an array containing 84 Phase I Enzyme drug metabolism genes. Results: The low ALT pediatric APAP overdose patients had higher (median [range]) ALT levels (35 [25,48] lUlL) compared to controls (16 [7, 20] IUIL). Three genes had significant downregulation that was later confirmed: GZMB (-2.86 fold, p<O.O I), ALDH6A 1 (-2.13 fold, p<O.Ol), and CYP4F12 (-4.04 fold, p<O.OS). Pathway analysis for the three genes pointed to signaling pathways connected to apoptosis, metabolism of valine and leucine (involved in the immune response), and hydroxylation of leukotriene B4 (involved in inflammation). Conclusion: Dysregulation of Phase I Enzyme drug metabolism pathways has relevance for understanding mechanisms of cell injury in APAP toxicity. Pathway analysis points to the potential for a weakened immune response associated with AP AP overdose. INTRODUCTION APAP toxicity does not have a clearly defined limit. Tylenol, the largest and most Acetaminophen (APAP) is a mild analgesic well-known distributer of APAP, recommends a found in many over-the-counter drugs. Taken in maximum daily dosage of 3,000 mg for adults. normal doses, it is generally regarded as safe For children, this amount greatly varies by and non-toxic, though liver injwy is common. weigh l and age [ I 0]. Nonetheless, the AP AP overdose is the leading cause of acute acetaminophen toxicity limit varies from person liver failure in the United States [6]. to person. Acetaminophen overdose is a common The clinical biomarker for APAP overdose is problem in the United States. A 2015 study alanine aminotransferase (ALT). Raised ALT (conducted from 2006-20 I 0) showed that in the levels indicate liver injwy, but this is not United States alone, 82,362 people visited the specific to acetaminophen (6]. APAP adducts emergency room every year for APAP arc fonncd in the metabolism of acetaminophen. overdose. Every year, there were roughly 494 AP AP is metabolized by Phase I enzymes in the deaths caused by acetaminophen toxicity [1]. cytochrome P450 family (namely CYP2El) into N-acetyl-p-benzoquinone imine (NAPQI), a toxic reactive intermediate metabolite. When 2 NAPQI binds to the cysteine group on a protein, selected with no AP AP influence in the last two APAP adducts are formed [7]. In a therapeutic weeks). dose of AP AP, this material is detoxified by RNA Isolation and eDNA Synthesis glutathione and is excreted. Thus, these adducts are only present in patients who have exceeded The PA.Xgcnc Blood miRNA system was the normal dosage of APAP and present liver used for the purification of total RNA from il\iury [6, 7]. peripheral blood collected in P A.Xgene Blood RNA Tubes. PAXgene-extracted RNA was The lab previously studied APAP overdose quantified using spectrophotometer in patients with severe liver injury, defined as (NanoDrop™ 1000, Thenno Fisher Scientific, having ALT levels >75 TU/L. The five high Wilmington, DE). eDNA synthesis was ALT blood samples were run in qPCR against performed using the RT2 First Strand kit five control samples, and three genes were (Qiagen). identified as being dowmegulated (using a 2- fold and p<0.05 cut-oft): ALDHlAl, Phase I PCR Array CYP27Al, and GZMB. The downregulation of all three genes was confirmed by individual For target gene expression analysis, Phase I analysis. Enzymes RP Profiler™ PCR Array (PAHS~ 068Z), which contains 84 genes involved in This study functioned as a follow-up to the Phase I drug metabolism, were used with the high ALT experiment and a conclusion to the SYBR®Green system (Qiagen). The ABI lab's PA.Xgene APAP overdose project. In this QuantStudio 6 Flex Real Time PCR cycler study, we investigated gene dysregulation of (Applied Biosystems) was used to perfonn APAP overdose patients who exhibited mild quantitative real-time PCR (qPCR). All liver injury, or low ALT levels, to better experiments were performed in DNase/RNase understand acetaminophen's pathway to cell free conditions and n01malized to GAPDH. The injury. analysis was performed by Threshold Cycle Method and the fold change obtained by the delta CT method. Qiagen's qPCR analysis tool, METHODS available on Sample Collection http://pcrdataanalysis.sabiosciences.com/pcr/arr ayanalysis.php, was used for analysis. The The study focused on pediatric AP AP Volcano plot considered genes that had 2:2 fold overdose patients with low AL T levels from change and a p-value <0.05 in the t-test. Arkansas Children's Hospital. Patients who were in the hospital due to AP AP overdose and eDNA Expression Analysis presented a mild liver injury, defined as ALT Quantitative real time PCR (qPCR) was levels <75 IU/L, were identified and selected for performed for all samples in triplicate on the study. Blood samples were collected by QuantStudioTM 6 Flex Real-Time PCR System nurses who were aware of the study and (TbermoFisher Scientific, Carlsbad, CA). qRT delivered to the lab for research. ALT levels and PCR quantification of eDNA expression was AP AP adduct levels were measured for each performed using assays and accompanying sample. Blood samples were stored in PAXgene reagents from Qiagen eDNA analyses were Blood RNA tubes (PreAnalytiX, GmbH, performed using Primer Assays for aldehyde Switzerland). This study included five AP AP dehydrogenase 6 family, member Al overdose samples (low ALT levels) and five (ALDH6A l; PPH16308B), Cytochrome P450 control samples (randomly identified and family 4, subfamily F, polypeptide 12 3 (CYP4Fl2, PPH01237F), Granzyme B (GZMB; The qpCR array, analyzed with the Qiagen PPH02594A), and Beta Actin ( ACTB; web portal qPCR analysis tool, identified three PPH00073G). For each primer assay, negative genes as dysregulated, defined as having a fold controls were run with water and eDNA change =:::2 and a p-value <0.05. They were samples. For no template controls (NTC) a identified on a volcano plot that plots -log( fold master mix with no eDNA was used. Data change) against -log(p-value) for each of the 84 normalization was performed with ACTB. genes profiled in the qPCR array (Figure Relative quantitation was calculated using the 2).ALDH6Al , GZMB, and CYP4F 12 were all delta CT method. Pathway analysis was identified as downrcgulated in the low ALT performed for each of the identified genes using APAP overdose samples. The individual qPCR The Human Gene Database available at validation assays confirmed the downrcgulation http://www.genecards.org/. of all three genes (Figure 3). GeneCards' reported pathway analysis shows that ALDH6Al is involved in metabolic RESULTS pathways in the degradation of valine, leucine, The ALT levels and AP AP adduct levels in and isoleucine [2]~ GZMB is involved in the the APA overdose low ALT group were Granzyme-B pathway of the immune response, significantly higher than those in the control specifically in apoptosis [4]; and CYP4Fl2 group, both with p-values <0.01 (Figure 1). catalyzes leukotriene B4 omega-hydroxylation [3]. Control 24 7 0.0001 30 10 0.0009 32 16 0.0038 36 18 0.008 38 14 Mean 13 0.0032 Low ALT 59 48 0.4403 60 25 0.6983 61 35 0.6663 69 33 0.7767 74 35 Mean 35.2 0.6454 Figure 1: Sample data for control and APAP overdose (low ALT) groups. The test group had higher ALT levels (p=0.0017) and significantly higher APAP adduct levels (p=0.0030). 4 ,, Nutmaliud to GAPDI {. 2-(nhl .lntl <IU)S p-value cutuf(s, ~ j : • ' l I ALIJIIt•AI ~. I 1 I ! ~ I ·l t I ·<~IFI2 I • i I • • • : I . • • I • ' • • ! ! #I• I • • • i ! • •.,. • I • i • I I .. , - I !' ·•, ; !' • ! .